Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor
cells in patients with colorectal cancer and liver metastases that can be removed by surgery.
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Dasatinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.